GSK Negotiating Potential $1 Billion Sale Of Two Thrombosis Drugs To Aspen
This article was originally published in The Pink Sheet Daily
Executive Summary
Reflecting its aim to jettison older products with declining sales, GlaxoSmithKline is considering an offer from South Africa-based generics maker Aspen Pharmacare for its branded heart medicines Arixtra and Fraxiparine and a related manufacturing site in France.